Cerebrolysin vs VIP
Both Cerebrolysin and VIP are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Cerebrolysin
Evidence BCerebrolysin (porcine brain peptide complex)
A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.
View full Cerebrolysin profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | Cerebrolysin | VIP |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | Trial range: 5–30 mL daily (intravenous infusion) | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 41 | 24 |
| Categories | cognitive, neuroprotection | anti-inflammatory, neuroprotection |
Key reported benefits — Cerebrolysin
- ✓Stroke recovery support
- ✓TBI rehabilitation
- ✓Cognitive function in dementia
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.